MX385085B - Uso de beta-agonistas del receptor de la hormona tiroidea. - Google Patents
Uso de beta-agonistas del receptor de la hormona tiroidea.Info
- Publication number
- MX385085B MX385085B MX2018012900A MX2018012900A MX385085B MX 385085 B MX385085 B MX 385085B MX 2018012900 A MX2018012900 A MX 2018012900A MX 2018012900 A MX2018012900 A MX 2018012900A MX 385085 B MX385085 B MX 385085B
- Authority
- MX
- Mexico
- Prior art keywords
- agonists
- hormone receptor
- thyroid hormone
- receptor beta
- beta
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326436P | 2016-04-22 | 2016-04-22 | |
| PCT/US2017/029120 WO2017185087A1 (en) | 2016-04-22 | 2017-04-24 | Use of thyroid beta-agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018012900A MX2018012900A (es) | 2019-07-01 |
| MX385085B true MX385085B (es) | 2025-03-14 |
Family
ID=60116400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012900A MX385085B (es) | 2016-04-22 | 2017-04-24 | Uso de beta-agonistas del receptor de la hormona tiroidea. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11351183B2 (enExample) |
| EP (1) | EP3445373B1 (enExample) |
| JP (1) | JP6931042B2 (enExample) |
| KR (1) | KR102407059B1 (enExample) |
| AU (1) | AU2017252126B2 (enExample) |
| BR (1) | BR112018071586A2 (enExample) |
| CA (1) | CA3021681C (enExample) |
| ES (1) | ES2992773T3 (enExample) |
| MX (1) | MX385085B (enExample) |
| WO (1) | WO2017185087A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017185087A1 (en) | 2016-04-22 | 2017-10-26 | Viking Therapeutics | Use of thyroid beta-agonists |
| CA3094167A1 (en) | 2018-03-22 | 2019-09-26 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| JP2007524656A (ja) | 2003-10-23 | 2007-08-30 | セルジーン・コーポレーション | 疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法 |
| EP1689383B1 (en) | 2003-11-19 | 2012-10-31 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| CN101072555B (zh) | 2004-12-08 | 2011-06-29 | 矫正诊疗公司 | 治疗与视黄醇有关的疾病的方法、分析和组合物 |
| US20090028925A1 (en) * | 2005-05-26 | 2009-01-29 | Erion Mark D | Novel Phosphinic Acid-Containing Thyromimetics |
| CA2606499C (en) | 2005-05-26 | 2017-06-13 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| EP1987827A1 (en) | 2006-02-20 | 2008-11-05 | Takeda Pharmaceutical Company Limited | Novel pharmaceutical |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| WO2011038207A1 (en) * | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| KR20230084331A (ko) | 2011-06-21 | 2023-06-12 | 알닐람 파마슈티칼스 인코포레이티드 | 아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법 |
| WO2014178892A1 (en) * | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| JP2018510849A (ja) | 2015-02-20 | 2018-04-19 | オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ | ソベチロムの誘導体 |
| CN108602613B (zh) | 2016-02-29 | 2020-06-16 | 菲利普莫里斯生产公司 | 铰接盖容器和坯料 |
| WO2017185083A1 (en) | 2016-04-22 | 2017-10-26 | Viking Therapeutics | Use of thyroid beta-agonists |
| WO2017185087A1 (en) | 2016-04-22 | 2017-10-26 | Viking Therapeutics | Use of thyroid beta-agonists |
| DK3457851T3 (da) | 2016-05-18 | 2021-09-20 | Univ Oregon Health & Science | Derivater af sobetirom |
-
2017
- 2017-04-24 WO PCT/US2017/029120 patent/WO2017185087A1/en not_active Ceased
- 2017-04-24 KR KR1020187033713A patent/KR102407059B1/ko active Active
- 2017-04-24 ES ES17786798T patent/ES2992773T3/es active Active
- 2017-04-24 CA CA3021681A patent/CA3021681C/en active Active
- 2017-04-24 EP EP17786798.3A patent/EP3445373B1/en active Active
- 2017-04-24 MX MX2018012900A patent/MX385085B/es unknown
- 2017-04-24 JP JP2019507069A patent/JP6931042B2/ja active Active
- 2017-04-24 US US16/095,228 patent/US11351183B2/en active Active
- 2017-04-24 AU AU2017252126A patent/AU2017252126B2/en active Active
- 2017-04-24 BR BR112018071586-7A patent/BR112018071586A2/pt not_active Application Discontinuation
-
2022
- 2022-05-06 US US17/738,621 patent/US11951114B2/en active Active
-
2024
- 2024-03-05 US US18/595,919 patent/US12440502B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018071586A2 (pt) | 2019-02-12 |
| CA3021681A1 (en) | 2017-10-26 |
| ES2992773T3 (en) | 2024-12-18 |
| JP2019515033A (ja) | 2019-06-06 |
| EP3445373B1 (en) | 2024-08-21 |
| WO2017185087A1 (en) | 2017-10-26 |
| MX2018012900A (es) | 2019-07-01 |
| EP3445373A1 (en) | 2019-02-27 |
| US20250000880A1 (en) | 2025-01-02 |
| US20190321379A1 (en) | 2019-10-24 |
| US11351183B2 (en) | 2022-06-07 |
| KR20190039027A (ko) | 2019-04-10 |
| AU2017252126B2 (en) | 2023-02-09 |
| AU2017252126A1 (en) | 2018-11-08 |
| KR102407059B1 (ko) | 2022-06-10 |
| CA3021681C (en) | 2024-09-24 |
| US11951114B2 (en) | 2024-04-09 |
| US20220257618A1 (en) | 2022-08-18 |
| JP6931042B2 (ja) | 2021-09-01 |
| EP3445373A4 (en) | 2019-12-18 |
| US12440502B2 (en) | 2025-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17063327A (es) | Receptores de antígeno quiméricos antidll3 y métodos de uso | |
| ECSP17031725A (es) | Receptores quiméricos de anitígeno anti-clon y métodos de uso | |
| MX386587B (es) | ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO. | |
| CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
| CL2017000590A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| EA201791117A1 (ru) | Частичные агонисты инсулинового рецептора | |
| EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
| CL2017001289A1 (es) | Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr). | |
| MX2016010433A (es) | Anticuerpos anti-jagged1 y metodos de uso. | |
| MX2017005920A (es) | Anticuerpos anti-tim3 y metodos de uso. | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| MY195115A (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
| MX376026B (es) | Inmunoreceptores especificos de claudina-6 y epitopos de celulas t. | |
| LT3183268T (lt) | Anti-cd123 chimerinis antigeno receptorius (car), skirtas naudoti vėžio gydymui | |
| ES2796903T8 (es) | Procedimiento de uso de inmunoconjugados anti-CD79b | |
| CO2017002159A2 (es) | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| MX384989B (es) | Uso de un agonista del receptor x retinoide (rxr) en combinación con una hormona tiroidea para el tratamiento de esclerosis múltiple. | |
| MX2016004853A (es) | Metodos de uso de anticuerpos anti-ly6e. | |
| CL2018003045A1 (es) | Semaglutida en afecciones cardiovasculares. | |
| MX384037B (es) | Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso. | |
| CO2019013718A2 (es) | Anticuerpos anti-trkb | |
| MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. | |
| EA201790373A1 (ru) | Способы получения модуляторов toll-подобных рецепторов | |
| EA201792312A1 (ru) | Конструкции на основе калихеамицина и способы их применения | |
| BR112018071586A2 (pt) | uso de beta-agonistas da tireoide |